Pneumocystis jirovecii Pneumonia

Infectious Disease Clinics of North America

Volumn 24, Issue 1, 2010, Pages 107-138

  Catherinot, Emilie ^a,b   Lanternier, Fanny ^a   Bougnoux, Marie Elisabeth ^a   Lecuit, Marc ^a   Couderc, Louis Jean ^b   Lortholary, Olivier ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

AIDS; Chemoprophylaxis; Pneumocystis jirovecii; Pulmonary infections

Indexed keywords

ATOVAQUONE; CASPOFUNGIN; CLINDAMYCIN; CORTICOSTEROID; DAPSONE; FOLIC ACID; METHOTREXATE; PENTAMIDINE; PREDNISONE; PRIMAQUINE; SULFADOXINE PLUS TRIMETHOPRIM; TRIMETHOPRIM;

ANAPHYLAXIS; BACTERIUM CULTURE; BACTERIUM DETECTION; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CYTOPENIA; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGLYCEMIA; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; METHEMOGLOBINEMIA; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; PANCREATITIS; PHYLOGENY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; RASH; REVIEW; SKIN MANIFESTATION; SOLID TUMOR; STEVENS JOHNSON SYNDROME; T CELL DEPLETION; TAXONOMY; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; VASCULAR DISEASE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS;

EID: 76749147048     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.10.010     Document Type: Review

References (246)

1. Delanoe P., and Delanoe M. [Sur les rapports des kystes de carinii du poumon des rats avec le Trypanosoma lewisi]. CR Acad Sci 155 (1912) 658-660 [in French]
2. Ammich O. [Uber die nichtsyphilitische interstitielle pneumoniae des ersten kindersalters]. Virchows Arch Pathol Anat 302 (1938) 539-554 [in German]
3. Van der Meer G., and Brug S.L. [Infection par Pneumocystis chez l'homme et chez les animaux]. Annales de la Société Belge de Médecine Tropicale 22 (1942) 301-305 [in French]
4. Vanek J., and Jirovec O. [Parasitaere pneumonie. Interstitielle plasmazellen pneumonie der fruehgeborenen verursacht durch Pneumocytis carinii]. Zentralbl Bakteriol 158 (1952) 120-127 [in German]
5. Sepkowitz K.A., Brown A.E., and Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155 11 (1995) 1125-1128
6. Ng V.L., Yajko D.M., and Hadley W.K. Extrapulmonary pneumocystosis. Clin Microbiol Rev 10 3 (1997) 401-418
7. Excler J.L., Mojon M., Guyonnet C., et al. [Pneumocystis carinii pneumonia in children. Apropos of 33 cases]. Pediatrie 39 7 (1984) 513-523 [in French]
8. Walzer P.D., Schultz M.G., Western K.A., et al. Pneumocystis carinii pneumonia and primary immune deficiency diseases. Natl Cancer Inst Monogr 43 (1976) 65-74
9. Gottlieb M.S., Schroff R., Schanker H.M., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305 24 (1981) 1425-1431
10. Masur H., Michelis M.A., Greene J.B., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 305 24 (1981) 1431-1438
11. Jaffe H.W., Bregman D.J., and Selik R.M. Acquired immune deficiency syndrome in the United States: the first 1,000 cases. J Infect Dis 148 2 (1983) 339-345
12. Gebo K.A., Fleishman J.A., and Moore R.D. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 40 5 (2005) 609-616
13. San-Andres F.J., Rubio R., Castilla J., et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 36 9 (2003) 1177-1185
14. Bonnet F., Lewden C., May T., et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 37 6-7 (2005) 482-487
15. Edman J.C., Kovacs J.A., Masur H., et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 334 6182 (1988) 519-522
16. Stringer S.L., Stringer J.R., Blase M.A., et al. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp Parasitol 68 4 (1989) 450-461
17. Redhead S.A., Cushion M.T., Frenkel J.K., et al. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 53 1 (2006) 2-11
18. Frenkel J.K. Pneumocystis jiroveci n. sp. from man: morphology, physiology, and immunology in relation to pathology. Natl Cancer Inst Monogr 43 (1976) 13-30
19. Walzer P.D., and Linke M.J. A comparison of the antigenic characteristics of rat and human Pneumocystis carinii by immunoblotting. J Immunol 138 7 (1987) 2257-2265
20. Stringer J.R., Beard C.B., Miller R.F., et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 8 9 (2002) 891-896
21. Li J., and Edlind T. Phylogeny of Pneumocystis carinii based on beta-tubulin sequence. J Eukaryot Microbiol 41 5 (1994) 97S
22. Mazars E., Odberg-Ferragut C., Dei-Cas E., et al. Polymorphism of the thymidylate synthase gene of Pneumocystis carinii from different host species. J Eukaryot Microbiol 42 1 (1995) 26-32
23. Ma L., and Kovacs J.A. Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother 44 11 (2000) 3092-3096
24. Banerji S., Lugli E.B., Miller R.F., et al. Analysis of genetic diversity at the arom locus in isolates of Pneumocystis carinii. J Eukaryot Microbiol 42 6 (1995) 675-679
25. Sinclair K., Wakefield A.E., Banerji S., et al. Pneumocystis carinii organisms derived from rat and human hosts are genetically distinct. Mol Biochem Parasitol 45 1 (1991) 183-184
26. Liu Y., Rocourt M., Pan S., et al. Sequence and variability of the 5.8s and 26s rRNA genes of Pneumocystis carinii. Nucleic Acids Res 20 14 (1992) 3763-3772
27. Denis C.M., Mazars E., Guyot K., et al. Genetic divergence at the soda locus of six different formae speciales of Pneumocystis carinii. Med Mycol 38 4 (2000) 289-300
28. Shah J.S., Pieciak W., Liu J., et al. Diversity of host species and strains of Pneumocystis carinii is based on rRNA sequences. Clin Diagn Lab Immunol 3 1 (1996) 119-127
29. Aliouat E.M., Mazars E., Dei-Cas E., et al. Pneumocystis cross infection experiments using SCID mice and nude rats as recipient host, showed strong host-species specificity. J Eukaryot Microbiol 41 5 (1994) 71S
30. Gigliotti F., Harmsen A.G., Haidaris C.G., et al. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 61 7 (1993) 2886-2890
31. Beard C.B., Jennings V.M., Teague W.G., et al. Experimental inoculation of immunosuppressed owl monkeys with Pneumocystis carinii f. sp. hominis. J Eukaryot Microbiol 46 5 (1999) 113S-115S
32. Stringer J.R., Cushion M.T., and Wakefield A.E. New nomenclature for the genus Pneumocystis. J Eukaryot Microbiol Suppl (2001) 184S-189S
33. Gigliotti F. Pneumocystis carinii: has the name really been changed?. Clin Infect Dis 41 12 (2005) 1752-1755
34. Cushion M.T., and Stringer J.R. Has the name really been changed? It has for most researchers. Clin Infect Dis 41 12 (2005) 1756-1758
35. Gigliotti F. Pneumocystis carinii nomenclature: response to cushion and stringer. Clin Infect Dis 42 8 (2006) 1208-1209
36. Thomas Jr. C.F., and Limper A.H. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 5 4 (2007) 298-308
37. Huang L., Morris A., Limper A.H., et al. An official ATS workshop summary: recent advances and future directions in Pneumocystis pneumonia (PCP). Proc Am Thorac Soc 3 8 (2006) 655-664
38. Yoneda K., and Walzer P.D. Attachment of Pneumocystis carinii to type I alveolar cells studied by freeze-fracture electron microscopy. Infect Immun 40 2 (1983) 812-815
39. Walzer P.D., and Smulian A.G. Pneumocystis species. In: Linvingstone C. (Ed). Principles and practice of infectious disease vol. 2 (2004), Elsevier 3080-3094
40. Limper A.H., and Martin II W.J. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. J Clin Invest 85 2 (1990) 391-396
41. Limper A.H., Edens M., Anders R.A., et al. Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest 101 5 (1998) 1148-1155
42. Limper A.H., Hoyte J.S., and Standing J.E. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 99 9 (1997) 2110-2117
43. Lasbury M.E., Durant P.J., Ray C.A., et al. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J Immunol 176 11 (2006) 6443-6453
44. Koziel H., Eichbaum Q., Kruskal B.A., et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 102 7 (1998) 1332-1344
45. Koziel H., Li X., Armstrong M.Y., et al. Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro. Am J Respir Cell Mol Biol 23 4 (2000) 452-459
46. Beck J.M., Warnock M.L., Kaltreider H.B., et al. Host defenses against Pneumocystis carinii in mice selectively depleted of CD4+ lymphocytes. Chest 103 Suppl 2 (1993) 116S-118S
47. Bhagwat S.P., Gigliotti F., Xu H., et al. Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol 291 6 (2006) L1256-L1266
48. Roths J.B., and Sidman C.L. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest 90 2 (1992) 673-678
49. Harmsen A.G., and Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 172 3 (1990) 937-945
50. Beck J.M., Newbury R.L., Palmer B.E., et al. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. J Lab Clin Med 128 5 (1996) 477-487
51. Wright T.W., Gigliotti F., Finkelstein J.N., et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 104 9 (1999) 1307-1317
52. Beck J.M., Warnock M.L., Curtis J.L., et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol 5 2 (1991) 186-197
53. Azoulay E., Parrot A., Flahault A., et al. AIDS-related Pneumocystis carinii pneumonia in the era of adjunctive steroids: implication of BAL neutrophilia. Am J Respir Crit Care Med 160 2 (1999) 493-499
54. Limper A.H., Offord K.P., Smith T.F., et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 140 5 (1989) 1204-1209
55. Benfield T.L., Vestbo J., Junge J., et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 151 4 (1995) 1058-1062
56. Swain S.D., Wright T.W., Degel P.M., et al. Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice. Infect Immun 72 10 (2004) 5722-5732
57. Wakefield A.E. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J Clin Microbiol 34 7 (1996) 1754-1759
58. Casanova-Cardiel L., and Leibowitz M.J. Presence of Pneumocystis carinii DNA in pond water. J Eukaryot Microbiol 44 6 (1997) 28S
59. Morris A., Beard C.B., and Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 4 1 (2002) 95-103
60. Wakefield A.E. Detection of DNA sequences identical to Pneumocystis carinii in samples of ambient air. J Eukaryot Microbiol 41 5 (1994) 116S
61. Respaldiza N., Medrano F.J., Medrano A.C., et al. High seroprevalence of Pneumocystis infection in Spanish children. Clin Microbiol Infect 10 11 (2004) 1029-1031
62. Vargas S.L., Hughes W.T., Santolaya M.E., et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 32 6 (2001) 855-861
63. Larsen H.H., von Linstow M.L., Lundgren B., et al. Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 13 1 (2007) 66-72
64. Morris A.M., Swanson M., Ha H., et al. Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco. Am J Respir Crit Care Med 162 5 (2000) 1622-1626
65. Dohn M.N., White M.L., Vigdorth E.M., et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 162 5 (2000) 1617-1621
66. Beard C.B., Carter J.L., Keely S.P., et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: Implications for transmission. Emerg Infect Dis 6 3 (2000) 265-272
67. Garvy B.A., and Qureshi M.H. Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J Immunol 165 11 (2000) 6480-6486
68. Chen W., Gigliotti F., and Harmsen A.G. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun 61 12 (1993) 5406-5409
69. An C.L., Gigliotti F., and Harmsen A.G. Exposure of immunocompetent adult mice to Pneumocystis carinii f. sp. muris by cohousing: growth of P. carinii f. sp. muris and host immune response. Infect Immun 71 4 (2003) 2065-2070
70. Gigliotti F., Harmsen A.G., and Wright T.W. Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun 71 7 (2003) 3852-3856
71. Chabe M., Dei-Cas E., Creusy C., et al. Immunocompetent hosts as a reservoir of Pneumocystis organisms: histological and RT-PCR data demonstrate active replication. Eur J Clin Microbiol Infect Dis 23 2 (2004) 89-97
72. Olsson M., Sukura A., Lindberg L.A., et al. Detection of Pneumocystis carinii DNA by filtration of air. Scand J Infect Dis 28 3 (1996) 279-282
73. Hughes W.T., Bartley D.L., and Smith B.M. A natural source of infection due to Pneumocystis carinii. J Infect Dis 147 3 (1983) 595
74. Arichi N., Kishikawa H., Mitsui Y., et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc 41 1 (2009) 170-172
75. de Boer M.G., Bruijnesteijn van Coppenraet L.E., Gaasbeek A., et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis 44 9 (2007) 1143-1149
76. Olsson M., Eriksson B.M., Elvin K., et al. Genotypes of clustered cases of Pneumocystis carinii pneumonia. Scand J Infect Dis 33 4 (2001) 285-289
77. Hennequin C., Page B., Roux P., et al. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis 14 2 (1995) 122-126
78. Branten A.J., Beckers P.J., Tiggeler R.G., et al. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrol Dial Transplant 10 7 (1995) 1194-1197
79. Singer C., Armstrong D., Rosen P.P., et al. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann Intern Med 82 6 (1975) 772-777
80. Hocker B., Wendt C., Nahimana A., et al. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 11 2 (2005) 330-332
81. Schmoldt S., Schuhegger R., Wendler T., et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 46 3 (2008) 966-971
82. Rabodonirina M., Vanhems P., Couray-Targe S., et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 10 10 (2004) 1766-1773
83. Montes-Cano M.A., de la Horra C., Dapena F.J., et al. Dynamic colonisation by different Pneumocystis jirovecii genotypes in cystic fibrosis patients. Clin Microbiol Infect 13 10 (2007) 1008-1011
84. Morris A., Wei K., Afshar K., et al. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 197 1 (2008) 10-17
85. Nevez G., Jounieaux V., Linas M.D., et al. High frequency of Pneumocystis carinii sp.f. hominis colonization in HIV-negative patients. J Eukaryot Microbiol 44 6 (1997) 36S
86. Huang L., Crothers K., Morris A., et al. Pneumocystis colonization in HIV-infected patients. J Eukaryot Microbiol 50 Suppl (2003) 616-617
87. Wakefield A.E., Lindley A.R., Ambrose H.E., et al. Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients. J Infect Dis 187 6 (2003) 901-908
88. Rabodonirina M., Raffenot D., Cotte L., et al. Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR. J Clin Microbiol 35 11 (1997) 2748-2751
89. Morris A., Kingsley L.A., Groner G., et al. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 18 5 (2004) 793-798
90. Sing A., Roggenkamp A., Autenrieth I.B., et al. Pneumocystis carinii carriage in immunocompetent patients with primary pulmonary disorders as detected by single or nested PCR. J Clin Microbiol 37 10 (1999) 3409-3410
91. Sing A., Geiger A.M., Hogardt M., et al. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J Clin Microbiol 39 7 (2001) 2717-2718
92. Matos O., Costa M.C., Correia I., et al. Pneumocystis jirovecii carriage in Portuguese immunocompetent patients: preliminary results. J Eukaryot Microbiol 50 Suppl (2003) 647-648
93. Probst M., Ries H., Schmidt-Wieland T., et al. Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 19 8 (2000) 644-645
94. Morris A., Sciurba F.C., Lebedeva I.P., et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 170 4 (2004) 408-413
95. Calderon E.J., Rivero L., Respaldiza N., et al. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis 45 2 (2007) e17-e19
96. Vidal S., de la Horra C., Martin J., et al. Pneumocystis jirovecii colonisation in patients with interstitial lung disease. Clin Microbiol Infect 12 3 (2006) 231-235
97. Miguez-Burbano M.J., Ashkin D., Rodriguez A., et al. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease. Int J Infect Dis 9 4 (2005) 208-217
98. Miguez-Burbano M.J., Burbano X., Ashkin D., et al. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict Biol 8 1 (2003) 39-43
99. Nevez G., Raccurt C., Vincent P., et al. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4+ T cell counts. Clin Infect Dis 29 5 (1999) 1331-1332
100. Maskell N.A., Waine D.J., Lindley A., et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 58 7 (2003) 594-597
101. Vargas S.L., Ponce C.A., Sanchez C.A., et al. Pregnancy and asymptomatic carriage of Pneumocystis jiroveci. Emerg Infect Dis 9 5 (2003) 605-606
102. Nevez G., Totet A., Pautard J.C., et al. Pneumocystis carinii detection using nested-PCR in nasopharyngeal aspirates of immunocompetent infants with bronchiolitis. J Eukaryot Microbiol Suppl (2001) 122S-123S
103. Totet A., Meliani L., Lacube P., et al. Immunocompetent infants as a human reservoir for Pneumocystis jirovecii: rapid screening by non-invasive sampling and real-time PCR at the mitochondrial large subunit rRNA gene. J Eukaryot Microbiol 50 Suppl (2003) 668-669
104. Vargas S.L., Ponce C.A., Galvez P., et al. Pneumocystis is not a direct cause of sudden infant death syndrome. Pediatr Infect Dis J 26 1 (2007) 81-83
105. Montes-Cano M.A., Chabe M., Fontillon-Alberdi M., et al. Vertical transmission of Pneumocystis jirovecii in humans. Emerg Infect Dis 15 1 (2009) 125-127
106. Miller R.F., Ambrose H.E., and Wakefield A.E. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 39 11 (2001) 3877-3882
107. Vargas S.L., Ponce C.A., Gigliotti F., et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 38 4 (2000) 1536-1538
108. Lundgren B., Elvin K., Rothman L.P., et al. Transmission of Pneumocystis carinii from patients to hospital staff. Thorax 52 5 (1997) 422-424
109. Wissmann G., Varela J.M., and Calderon E.J. Prevention of Pneumocystis pneumonia in patients with inflammatory bowel disease based on the detection of Pneumocystis colonization. Inflamm Bowel Dis 14 12 (2008) 1751-1752
110. Mori S., Cho I., Ichiyasu H., et al. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy. Mod Rheumatol 18 3 (2008) 240-246
111. Christensen P.J., Preston A.M., Ling T., et al. Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice. Infect Immun 76 8 (2008) 3481-3490
112. Norris K.A., Morris A., Patil S., et al. Pneumocystis colonization, airway inflammation, and pulmonary function decline in acquired immunodeficiency syndrome. Immunol Res 36 1-3 (2006) 175-187
113. Vargas S.L., Ponce C.A., Hughes W.T., et al. Association of primary Pneumocystis carinii infection and sudden infant death syndrome. Clin Infect Dis 29 6 (1999) 1489-1493
114. Masur H., Ognibene F.P., Yarchoan R., et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 111 3 (1989) 223-231
115. Phair J., Munoz A., Detels R., et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 322 3 (1990) 161-165
116. D'Egidio G.E., Kravcik S., Cooper C.L., et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count <200 cells/microl when viral replication is suppressed. AIDS 21 13 (2007) 1711-1715
117. Kovacs J.A., and Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 301 24 (2009) 2578-2585
118. Walzer P.D., Evans H.E., Copas A.J., et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 46 4 (2008) 625-633
119. Pillonel J. [Surveillance de l'infection par le VIH/SIDA en France, 2006]. Bull Épidémiol Hebd 46-47 (2007) 386-393 [in French]
120. Mikaelsson L., Jacobsson G., and Andersson R. Pneumocystis pneumonia-a retrospective study 1991-2001 in Gothenburg, Sweden. J Infect 53 4 (2006) 260-265
121. Hui M., and Kwok W.T. Pneumocystis carinii pneumonia in Hong Kong: a 10 year retrospective study. J Med Microbiol 55 Pt 1 (2006) 85-88
122. Arend S.M., Kroon F.P., and van't Wout J.W. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 155 22 (1995) 2436-2441
123. Russian D.A., and Levine S.J. Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci 321 1 (2001) 56-65
124. Overgaard U.M., and Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 39 6-7 (2007) 589-595
125. Sepkowitz K.A., Brown A.E., Telzak E.E., et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267 6 (1992) 832-837
126. Leggiadro R.J., Winkelstein J.A., and Hughes W.T. Prevalence of Pneumocystis carinii pneumonitis in severe combined immunodeficiency. J Pediatr 99 1 (1981) 96-98
127. Walzer P.D., Schultz M.G., Western K.A., et al. Pneumocystis carinii pneumonia and primary immune deficiency diseases of infancy and childhood. J Pediatr 82 3 (1973) 416-422
128. Levy J., Espanol-Boren T., Thomas C., et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 131 1 Pt 1 (1997) 47-54
129. Winkelstein J.A., Marino M.C., Ochs H., et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82 6 (2003) 373-384
130. Imai K., Morio T., Zhu Y., et al. Clinical course of patients with wasp gene mutations. Blood 103 2 (2004) 456-464
131. Elhasid R., and Etzioni A. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev 10 4 (1996) 242-248
132. Richman D.D., Zamvil L., and Remington J.S. Recurrent Pneumocystis carinii pneumonia in a child with hypogammaglobulinemia. Am J Dis Child 125 1 (1973) 102-103
133. Dittrich A.M., Schulze I., Magdorf K., et al. X-linked agammaglobulinaemia and Pneumocystis carinii pneumonia-an unusual coincidence?. Eur J Pediatr 162 6 (2003) 432-433
134. Burke B.A., and Good R.A. Pneumocystis carinii infection. Medicine (Baltimore) 52 1 (1973) 23-51
135. Lund F.E., Hollifield M., Schuer K., et al. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176 10 (2006) 6147-6154
136. Alibrahim A., Lepore M., Lierl M., et al. Pneumocystis carinii pneumonia in an infant with X-linked agammaglobulinemia. J Allergy Clin Immunol 101 4 Pt 1 (1998) 552-553
137. Adinoff A.D., Johnston Jr. R.B., Dolen J., et al. Chronic granulomatous disease and Pneumocystis carinii pneumonia. Pediatrics 69 1 (1982) 133-134
138. Rosenszweig S.D., and Holland S.M. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 113 4 (2004) 620-626
139. Kovacs J.A., Hiemenz J.W., Macher A.M., et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100 5 (1984) 663-671
140. Yale S.H., and Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71 1 (1996) 5-13
141. Pagano L., Fianchi L., Mele L., et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in gimema centres. Br J Haematol 117 2 (2002) 379-386
142. Cheson B.D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13 9 (1995) 2431-2448
143. Byrd J.C., Hargis J.B., Kester K.E., et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 49 2 (1995) 135-142
144. Morra E., Nosari A., and Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 41 4 (1999) 145-151
145. Roblot F., Imbert S., Godet C., et al. Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scand J Infect Dis 36 11-12 (2004) 848-854
146. De Castro N., Pavie J., Lagrange-Xelot M., et al. [Pneumocystis jiroveci pneumonia in patients with cancer: is it unavoidable?]. Rev Mal Respir 24 6 (2007) 741-750 [in French]
147. Martin S.I., Marty F.M., Fiumara K., et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43 1 (2006) 16-24
148. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 3 (2002) 768-773
149. Otahbachi M., Nugent K., and Buscemi D. Granulomatous Pneumocystis jiroveci pneumonia in a patient with chronic lymphocytic leukemia: a literature review and hypothesis on pathogenesis. Am J Med Sci 333 2 (2007) 131-135
150. Morrison V.A. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia. Expert Rev Anticancer Ther 1 1 (2001) 84-90
151. Kolstad A., Holte H., Fossa A., et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92 1 (2007) 139-140
152. Venhuizen A.C., Hustinx W.N., van Houte A.J., et al. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 80 3 (2008) 275-276
153. Varthalitis I., and Meunier F. Pneumocystis carinii pneumonia in cancer patients. Cancer Treat Rev 19 4 (1993) 387-413
154. Henson J.W., Jalaj J.K., Walker R.W., et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 48 4 (1991) 406-409
155. Kulke M.H., and Vance E.A. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 25 2 (1997) 215-218
156. Godeau B., Coutant-Perronne V., Le Thi Huong D., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 21 2 (1994) 246-251
157. Ognibene F.P., Shelhamer J.H., Hoffman G.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 151 3 Pt 1 (1995) 795-799
158. Kadoya A., Okada J., Iikuni Y., et al. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 23 7 (1996) 1186-1188
159. Alarcon G.S. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 20 4 (2006) 849-875
160. Marie E. [Infections au cours des polymyosites et des dermatomyosites]. Presse Med 38 (2009) 303-316 [in French]
161. Bachelez H., Schremmer B., Cadranel J., et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med 157 13 (1997) 1501-1503
162. Smith M.B., and Hanauer S.B. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med 327 (1992) 497-498
163. Bernstein C.N., Kolodny M., Block E., et al. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with steroids. Am J Gastroenterol 88 (1993) 574-577
164. Kaur N., and Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 52 6 (2007) 1481-1484
165. Komano Y., Harigai M., Koike R., et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61 3 (2009) 305-312
166. Gordon S.M., LaRosa S.P., Kalmadi S., et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?. Clin Infect Dis 28 2 (1999) 240-246
167. Hardy A.M., Wajszczuk C.P., Suffredini A.F., et al. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis 149 2 (1984) 143-147
168. Lufft V., Kliem V., Behrend M., et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 62 3 (1996) 421-423
169. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60 3 (1995) 225-232
170. Dominguez J., Mahalati K., Kiberd B., et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 70 8 (2000) 1244-1247
171. Radisic M., Lattes R., Chapman J.F., et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 5 2 (2003) 84-93
172. Arend S.M., Westendorp R.G., Kroon F.P., et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 22 6 (1996) 920-925
173. Neff R.T., Jindal R.M., Yoo D.Y., et al. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 88 1 (2009) 135-141
174. Shapiro R., Young J.B., Milford E.L., et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5 4 (2005) 874-886
175. Issa N.C., and Fishman J.A. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 48 6 (2009) 772-786
176. Anderson K.C., Soiffer R., DeLage R., et al. T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood 76 1 (1990) 235-244
177. Tuan I.Z., Dennison D., and Weisdorf D.J. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 10 3 (1992) 267-272
178. De Castro N., Neuville S., Sarfati C., et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36 10 (2005) 879-883
179. Duncan R.A., von Reyn C.F., Alliegro G.M., et al. Idiopathic CD4+ T-lymphocytopenia-four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med 328 6 (1993) 393-398
180. Tarr P.E., Sneller M.C., Mechanic L.J., et al. Infections in patients with immunodeficiency with thymoma (good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore) 80 2 (2001) 123-133
181. Al Soub H., Taha R.Y., El Deeb Y., et al. Pneumocystis carinii pneumonia in a patient without a predisposing illness: case report and review. Scand J Infect Dis 36 8 (2004) 618-621
182. Hughes W.T. Pneumocystis carinii infections in mothers, infants and non-AIDS elderly adults. In: Sattler F.R., and Walzer P.D. (Eds). Pneumocystis carinii clinical infectious diseases vol. 2 (1995), Bailliere Tindall, London 461-470
183. Graham B.S., and Tucker Jr. W.S. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 101 3 (1984) 334-338
184. Abernathy-Carver K.J., Fan L.L., Boguniewicz M., et al. Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 18 3 (1994) 135-138
185. Oosterhuis J.K., van den Berg G., Monteban-Kooistra W.E., et al. Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome. Neth J Med 65 6 (2007) 215-217
186. Walzer P.D., Perl D.P., Krogstad D.J., et al. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 80 1 (1974) 83-93
187. Sepkowitz K.A., Telzak E.E., Gold J.W., et al. Pneumothorax in AIDS. Ann Intern Med 114 6 (1991) 455-459
188. Munoz P., Munoz R.M., Palomo J., et al. Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule. Medicine (Baltimore) 76 6 (1997) 415-422
189. Boiselle P.M., Crans Jr. C.A., and Kaplan M.A. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol 172 5 (1999) 1301-1309
190. Kennedy C.A., and Goetz M.B. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch Intern Med 152 7 (1992) 1390-1398
191. Jules-Elysee K.M., Stover D.E., Zaman M.B., et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med 112 10 (1990) 750-757
192. Thomas Jr. C.F., and Limper A.H. Pneumocystis pneumonia. N Engl J Med 350 24 (2004) 2487-2498
193. Pitchenik A.E., Ganjei P., Torres A., et al. Sputum examination for the diagnosis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am Rev Respir Dis 133 2 (1986) 226-229
194. O'Brien R.F., Quinn J.L., Miyahara B.T., et al. Diagnosis of Pneumocystis carinii pneumonia by induced sputum in a city with moderate incidence of AIDS. Chest 95 1 (1989) 136-138
195. Kovacs J.A., Ng V.L., Masur H., et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med 318 10 (1988) 589-593
196. Fujisawa T., Suda T., Matsuda H., et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology 14 2 (2009) 203-209
197. Ribes J.A., Limper A.H., Espy M.J., et al. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol 35 4 (1997) 830-835
198. Flori P., Bellete B., Durand F., et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 53 Pt 7 (2004) 603-607
199. Azoulay E., Bergeron A., Chevret S., et al. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 135 3 (2009) 655-661
200. Wharton J.M., Coleman D.L., Wofsy C.B., et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 105 1 (1986) 37-44
201. Sattler F.R., Cowan R., Nielsen D.M., et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 109 4 (1988) 280-287
202. Klein N.C., Duncanson F.P., Lenox T.H., et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 6 3 (1992) 301-305
203. O'Brien J.G., Dong B.J., Coleman R.L., et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 24 5 (1997) 854-859
204. Safrin S., Finkelstein D.M., Feinberg J., et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 124 9 (1996) 792-802
205. Toma E., Fournier S., Dumont M., et al. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin Infect Dis 17 2 (1993) 178-184
206. Leoung G.S., Mills J., Hopewell P.C., et al. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 105 1 (1986) 45-48
207. Dohn M.N., Weinberg W.G., Torres R.A., et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med 121 3 (1994) 174-180
208. Rosenberg D.M., McCarthy W., Slavinsky J., et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 15 2 (2001) 211-214
209. Mu X.D., Que C.L., He B., et al. Caspofungin as salvage treatment of severe Pneumocystis pneumonia: case report and literature review. Chin Med J (Engl) 122 8 (2009) 996-999
210. Hof H., and Schnulle P. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin. Mycoses 51 Suppl 1 (2008) 65-67
211. Utili R., Durante-Mangoni E., Basilico C., et al. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe Pneumocystis pneumonia in solid organ transplant recipients. Transplantation 84 6 (2007) 685-688
212. Benfield T., Atzori C., Miller R.F., et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr 48 1 (2008) 63-67
213. Toma E., Fournier S., Poisson M., et al. Clindamycin with primaquine for Pneumocystis carinii pneumonia. Lancet 1 8646 (1989) 1046-1048
214. Noskin G.A., Murphy R.L., Black J.R., et al. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis 14 1 (1992) 183-188
215. Navin T.R., Beard C.B., Huang L., et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet 358 9281 (2001) 545-549
216. Crothers K., Beard C.B., Turner J., et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 19 8 (2005) 801-805
217. Kazanjian P., Armstrong W., Hossler P.A., et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis 183 5 (2001) 819-822
218. Briel M., Bucher H.C., Boscacci R., et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 3 (2006) CD006150
219. Bozzette S.A., Sattler F.R., Chiu J., et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 323 21 (1990) 1451-1457
220. Pareja J.G., Garland R., and Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 113 5 (1998) 1215-1224
221. Delclaux C., Zahar J.R., Amraoui G., et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 29 3 (1999) 670-672
222. Mansharamani N.G., Garland R., Delaney D., et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118 3 (2000) 704-711
223. Gerrard J.G. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 162 5 (1995) 233-235
224. Roblot F., Godet C., Le Moal G., et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 21 7 (2002) 523-531
225. Roblot F., Le Moal G., Godet C., et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 47 1 (2003) 19-27
226. Bollee G., Sarfati C., Thiery G., et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 132 4 (2007) 1305-1310
227. Masur H., Kaplan J.E., and Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 137 5 Pt 2 (2002) 435-478
228. Green H., Paul M., Vidal L., et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82 9 (2007) 1052-1059
229. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33 2 (2001) 139-144
230. Fishman J.A. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 33 8 (2001) 1397-1405
231. Trotter J.F., Levi M., Steinberg T., et al. Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis. Transpl Infect Dis 10 5 (2008) 369-371
232. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.7.1. Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 17 S4 (2002) 36-39
233. Godeau B., Mainardi J.L., Roudot-Thoraval F., et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis 54 12 (1995) 991-994
234. Bozzette S.A., Finkelstein D.M., Spector S.A., et al. A randomized trial of three anti-Pneumocystis agents in patients with advanced human immunodeficiency virus infection. Niaid AIDS clinical trials group. N Engl J Med 332 11 (1995) 693-699
235. Bucher H.C., Griffith L., Guyatt G.H., et al. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 15 2 (1997) 104-114
236. Stein D.S., Stevens R.C., Terry D., et al. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 35 9 (1991) 1705-1709
237. Schneider M.M., Hoepelman A.I., Eeftinck Schattenkerk J.K., et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS treatment group. N Engl J Med 327 26 (1992) 1836-1841
238. Antinori A., Murri R., Ammassari A., et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 9 12 (1995) 1343-1350
239. Hirschel B., Lazzarin A., Chopard P., et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 324 16 (1991) 1079-1083
240. Casale L., Gold H., Schechter C., et al. Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency. Chest 103 2 (1993) 342-344
241. Kazanjian P.H., Fisk D., Armstrong W., et al. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and china. J Infect Dis 189 9 (2004) 1684-1687
242. Kazanjian P., Locke A.B., Hossler P.A., et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12 8 (1998) 873-878
243. Takahashi T., Hosoya N., Endo T., et al. Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. J Clin Microbiol 38 9 (2000) 3161-3164
244. Mei Q., Gurunathan S., Masur H., et al. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet 351 9116 (1998) 1631-1632
245. Ma L., Borio L., Masur H., et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 180 6 (1999) 1969-1978
246. Nahimana A., Rabodonirina M., Bille J., et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 48 11 (2004) 4301-4305